Abdominal/gastrointestinal complaints are the most prevalent initial symptoms in DLBCL, reported by 26% of patients. Peripheral lymphadenopathy and testicular tumors are associated with low-risk ...
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk. The treatment landscape for newly diagnosed diffuse large B-cell lymphoma is on the ...
In the article that accompanies this editorial, Bartlett et al 11 present the results of ECHELON-3, a phase III trial comparing brentuximab vedotin + lenalidomide + rituximab (BV + Len + R) with ...
Panelists discuss how exciting new data from ASH 2024 on bispecific therapies for B-cell lymphomas, including epcoritamab in diffuse large B-cell lymphoma, mosunetuzumab in follicular lymphoma, and ...
Real-time ctDNA MRD testing guides early chemo de-escalation in diffuse large B-cell lymphoma, aiming to cut toxicity without losing cure rates. In an interview with Targeted Oncology, Hua-Jay “Jeff” ...
Stories by SWNS on MSN
Dad-of-four told his leg pain was sciatica – then doctors gave him months to live
A dad-of-four who was told his leg pain was sciatica was later diagnosed with an aggressive cancer – and given just months to ...
Debi Weiss went to the doctor's office with what she thought were worsening flu symptoms, but got a very different diagnosis ...
Epigenetic therapies are offering a more targeted way to treat some lymphomas by changing how genes are turned on or off ...
Columbia University investigators report an increased risk of breast lymphomas after postmastectomy implant-based reconstruction, including anaplastic large-cell lymphoma and several B-cell and T-cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results